Read this topic

PlaceboAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more → and nocebo effects matter because they explain why patients can improve, or worsen, from a treatment with no active ingredient, purely from what they expect. Placebo is a genuine symptom improvement (a real physiological change, not just reporting biasA systematic error that skews a study's results away from the truth in a particular direction.Read more →) following an inert treatment, driven by expectation, conditioning (a learned association from earlier treatment experiences), and the meaning and ritual of receiving care. Nocebo is the mirror image: negative expectation produces genuinely adverse symptoms from an inert substance. For example, imagine a patient told a sugar pill is a strong painkiller who then reports real pain relief, that shows placebo analgesia (pain relief triggered by expectation) in action. In practice, this expectation effect is large enough that any new drug trial must control for it.

The placeboAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more → response is partly mediated by endogenous opioids (the body's own morphine-like painkillers) and dopamine release, which is why placebo analgesia can be partly reversed by naloxone (an opioid antagonistA drug that blocks a receptor, stopping it from being activated.Read more → drug). A warm, confident doctor-patient relationship, and a clear expectation of benefit, enhances the placebo response, while an alarming or pessimistic framing of side effects drives the nocebo response. For example, imagine a clinician who lists every possible side effect in a frightening tone before starting a new antidepressant. Some patients on the active drug then report those symptoms anyway, purely because they expected them. Because the placebo response can be large, drug trials need a placebo control group, randomisation (random allocation to treatment or placebo), and blindingKeeping participants and/or researchers unaware of who is receiving which treatment, to stop that knowledge from influencing results.Read more → (concealing which treatment a patient receives) to separate a drug's true effect from expectation. In practice, this means an uncontrolled 'before and after' improvement in a patient cannot be assumed to be the drug working.

• What happens when patients are told openly that the tablet they are taking is a placeboAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more →?
• Which tension does the nocebo effect create when consenting a patient to treatment?
• Which two mechanisms are thought to produce the placeboAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more → response?

• Spontaneous recovery, symptoms resolve with time and no expectation of treatment, unlike placebo'sAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more → expectation-driven improvement.
• Regression to the mean, extreme baseline measurements naturally move toward average on retesting, rather than reflecting a genuine treatment or placeboAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more → effect.
• Hawthorne effect, behaviour changes purely from being observed, unlike placebo'sAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more → link to belief in a treatment's benefit.
• Nocebo, negative expectation causes adverse symptoms, whereas placebo'sAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more → positive expectation causes symptom improvement.

• Worsening is not the observed result.
• A signature does not substitute for the discussion itself.
• Benefit persists in a proportion of patients despite full disclosure.
• These are conducted as ordinary randomised trials.
• Recruitment to open-label placeboAn inactive treatment given to a comparison group so any real effect of the active treatment can be judged against it.Read more → trials has proved feasible.

• Name the learning, social or research principle being tested before reading the options.
• Identify the antecedent, behaviour, consequence or cognitive process in the vignette.
• Compare the direction of effect with the nearest competing principle.
• Apply the same rule to a new example to confirm that the answer transfers.